FUNGUS INFECTIONS
The dermatophyte (ringworm) fungi are a
distinct and unique class of fungi, both
botanically and pathologically. Most commonly,
infection is acquired from another person, though
it may also be transmitted in soil or acquired
from animals. Dermatophyte fungi attach to,
proliferate, and live in the superficial layers of
the epidermis, in nails and in hair.
Contributing factors which may predispose to
infection include inadequate nutrition, improper
hygiene, warm climate and contact with infected
persons, animals or fomites(infected clothing).
Although pathogenic fungi of all kinds are
common in our environment, the overall incidence
remains low, probably as a result of undefined host
resistance factors.
Each species of dermatophyte tends to produce a
specific clinical picture, but it may be
difficult to ascertain the exact organism from
the characteristics of the eruption alone.
Common clinical types of infection include
Tinea Capitis (scalp ringworm) Tinea Manum
(hands)
Tinea Barbae (infection of beard or mustache)
Tinea Pedis (feet)
Tinea Corporis (infection of non-hairy skin)
Onychomycosis (nails)
Tinea Cruris ("jock itch")
Treatment
Therapy includes avoidance of prolonged
moisture, especially in areas such as the feet and
groin. Thorough drying of the skin with a hair
dryer can be helpful.
Avoid tightly or poor fitting shoes. Change
clothing and towels frequently and wash them in hot
water.
Topical antifungal medications, like tolnaftate
(Tinactin), miconazole (MicaTin) and clotrimazole
(Lotrimin, Mycelex) are extremely effective in many
cases. Many of these medications are available
without a prescription. In more resistant infections,
such as nail infections, oral antifungal medication
such as ketoconazole (Nizoral), itraconazole
(Sporanox) or terbinafine (Lamisil) may be required.
These medications can be expensive and require
periodic monitoring. Your health care provider
will suggest the treatment most likely to help your
particular case. If you do not improve within 10-14
days of beginning treatment (in the case of
topical medications), return to Health
Services for re-evaluation.
updated July 2, 2003